State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011
|
|
- Winfred Lee Jackson
- 5 years ago
- Views:
Transcription
1 State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011 Jubilee Brown, M.D. Associate Professor UT M.D. Anderson Cancer Center
2
3 Ovarian Cancer 21,880 new cases projected for 2010» 25,580 in ,850 deaths in US for 2010» 16,090 in % of all cancers 6% of all deaths -Jemal A, CA Cancer J Clin, 2010
4 Ovarian Cancer 90% are epithelial ovarian tumors 7% are sex cord-stromal tumors Different from more common epithelial type» Typical ovarian cancer research does not apply
5 WHO Classification (1973) Epithelial Sex cord-stromal Germ cell Soft tissue tumors not specific to the ovary Unclassified Secondary (metastatic) Tumor-like conditions (pregnancy luteoma, etc.)
6 WHO Classification - SCST Granulosa stromal cell» Granulosa cell» Thecoma-fibroma Androblastomas; Lipid Sertoli-Leydig cell cell Gynandroblastoma Unclassified
7 Adult GCT
8 Angiogenesis CD31: High MVD score, mean MVD of 48.4 CD31: Low MVD score, mean MVD of 7.4
9 The Story of GCT Research
10 Surgical Therapy - standard Childbearing complete: complete hysterectomy Fertility desired: Take out the involved tube and ovary BUT conserve the other normal ovary and the uterus in patients with limited disease Staging is still necessary Gershenson DM (2005) JNCI Monographs 34:43-7
11 Conservative Management
12 Post-surgical therapy Limited information Most institutions have only a few patients Published studies are limited» Combine histologic subtypes» Recommendations for rare tumors based on limited data Tend to progress or recur over many years even decades; need long-term follow-up
13 Post-surgical therapy How do you get past the pile of piranhas to see what s really there?
14 Post-surgical therapy: Sertoli-Leydig Cell Tumors Over 90% are Stage IA tumors Stage correlates with grade:» 100% of well differentiated tumors are stage IA» Only 52% of poorly differentiated tumors are stage IA Higher grade is associated with malignant behavior» 10% intermediate, 60% poorly diff, 20% retiform/heterologous show malignant behavior Recommendation is to treat:» Any patient with stage IC or greater» Poorly differentiated tumors of any stage (including IA)» Heterologous elements of any stage (including IA) -Brown J, Gershenson DM (2006) Treatment for Rare Ovarian Malignancies. M. D. Anderson Cancer Care Series Gynecologic Cancer. Springer-Verlag -Gordon MD, Ireland K (1995) Clin Lab Med 15:595
15 DATA - Platinum Slayton/GOG FAC 3/7 CR Schwartz 1976 FAC 2 CR Jacobs Doxo/Cis 2 PR Camlibel 1983 CAP 1 CR Kaye 1986 CAP 1 CR Neville 1984 Altretamine/Cis 2 PR
16 Treatment Surgery BVP (Colombo, Zambetti) 9/11 responses, severe toxicity BEP (Gershenson)
17 Gershenson BEP 9 patients with advanced SCST 83% 1 (Bleomycin, etoposide, cisplatin) RR / 7 durable remissions -Gershenson DM et al (1996) Obstet Gynecol 87:
18 Homesley (GOG 115) BEP x 4 75 patients, 18 excluded 57 patients Stage II IV disease 61% Grade 4 myelotoxicity -Homesley HD et al (1999). Gynecol Oncol 72:
19 BEP Regimen Bleomycin 20 units/m2 q week x 9 w Yielded 2 fatalities, so Bleomycin 20 units/m2 q 3 weeks x 4 Etoposide Cisplatin 75 mg/m2 QD x 5d q3w x 4 20 mg/m2 d1-5 q3w x 4
20 Bleomycin Discontinue if» DLCO decreases by 30%» Rales» Lack of expansion on examination
21 Homesley (GOG 115) % 69% had negative 2nd look surgery of advanced stage primary & 51% of patients with recurrence remained progression free
22 GOG 115 (Homesley) 6 complete responders had 24.4 month duration of response Only one with advanced disease had durable remission 4 pulmonary toxicity (2 deaths)
23 Problems with BEP Limited response to toxic chemotherapy Duration of response was 24 months Only 1 of 7 patients with advanced disease had durable remission Severe pulmonary fibrosis from bleomycin deaths) Second malignancies leukemia Hematologic toxicity (2
24 First Investigation The activity of taxanes in the treatment of sex cord-stromal ovarian tumors Purpose: To determine the efficacy and side effects of taxane-based chemotherapy for SCST -Brown J et al (2004) J Clin Oncol 22:
25 Taxanes in SCST 222 patients with SCST; 44 received a taxane 11 newly diagnosed» 9 adjuvant: Median PFS and OS not reached at 51 months» 2 with measurable disease: 1 CR, 1 not evaluable» Overall: PFS 34 months with median F\U 90 months 37 patients with recurrent disease (7 NMD, 30 MD)» NMD: 86% remained progression free, PFS 34 months» MD: 60% remained progression free, RR 42%, PFS 20 months -Brown J et al (2004) J Clin Oncol 22:
26 Taxanes in SCST Toxicity»»»»» Neutropenia (n = 6) Anemia (n = 1) Thrombocytopenia (n = 1) Myelodysplasia (n = 1) Hypersensitivity (n = 1) -Brown J et al (2004) J Clin Oncol 22:
27 Taxanes in SCST Conclusions:» Taxanes appear to have efficacy in treating SCST» Toxicity appears to be limited and acceptable -Brown J et al (2004) J Clin Oncol 22:
28 Next Investigation The activity of taxanes compared with BEP in the treatment of sex cord-stromal ovarian tumors Purpose: To compare the use of taxanes +/platinum with BEP in patients with SCST -Brown J et al (2005) Gynecol Oncol 97:
29 Newly Diagnosed Patients 22 patients: 11 BEP, 11 Taxane Length of F/U: 87 months BEP Taxane P NED 9/11 (82%) 9/11 (82%) 1 PFS 46 m NR (52+ m) OS 97 m NR (52+ m) 0.994
30 Recurrent Measurable Disease 37 patients: 7 BEP, 30 Taxane BEP n = 7 Taxanes n = 30 P CR 2 2 PR 3 9 Stable 0 6 Prog 2 12 RR 72% 37% FTP 72% 57% 0.727
31 Presence of platinum important! No platinum: Total response rate: 18% Platinum: Total response rate: 54% Compared with 18%, P = Comparing tx episodes, P = 0.027
32 Toxicity BEP (5/21 patients)» 3 pulmonary fibrosis,» 2 grade 4 neutropenia Taxane (6/44 patients)» 4 grade 4 neutropenia» 1 hypersensitivity» 1 myelodysplasia DLCO
33 Conclusions Taxane-based chemotherapy appears to be as effective as BEP for newly diagnosed and recurrent SCST Taxane-based chemotherapy may be less toxic than BEP for SCST This warrants further study
34 GOG 264 A Randomized Phase II Trial of Paclitaxel and Carboplatin versus Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex CordStromal Tumors of the Ovary
35 GOG 264
36 GOG 264 Opened February 2010 Accrual: Push 4/128 to open! International Finally, tumors interest support and funding for rare
37 Recurrent disease? GOG 187 opened November 2000 Single agent paclitaxel» First-line (newly diagnosed) arm 0/45 patients accrued, so replaced with GOG 251» Second-line (recurrent) arm 28/45 patients accrued
38 What about something informed by science? Something novel No natural lymphatic supply to granulosa cells May rely on angiogenesis for vascular supply Anecdotally, very few instances of LN mets
39 LN metastasis is extremely rare in SCSTs It many not be necessary to include routine lymphadenectomy in the staging of patients with SCSTs Nodal metastasis may be a secondary event
40 Patterns of metastasis in SCSTs: Can routine staging lymphadenectomy be omitted? 257 evaluable patients 111 had complete or partial staging procedure 52% had LN removed (n = 58 patients) None had positive nodes 117 patients eventually developed recurrent disease» Only 6 patients (5.1%) had nodal metastases
41 Patterns of metastasis in SCSTs: Can routine staging lymphadenectomy be omitted? Conclusions» LN metastasis is extremely rare in SCSTs» It may not be necessary to include routine lymphadenectomy in the staging of patients with SCSTs» Our findings suggest that nodal metastasis is a secondary event Brown J, et al. Gynecol Oncol, 113:86-90, 4/2009.
42 If LN metastasis is rare and distant metastasis is common Characterize lymphatic supply to granulosa cell tumors and SCSTs Characterize angiogenesis may play a prominent role» Tumors are highly vascular» Distant metastases are common
43 CT of Pelvis
44 PET/CT: Sertoli-Leydig
45 We know these tumors are vascular:
46 We know these tumors are vascular:
47 We know these tumors are vascular:
48 What does that mean clinically? 80 tumor samples from 65 patients Stained for CD31 (MVD), VEGF, and D2-40 (LVD) Correlated with clinical data
49 Clinical relevance of angiogenesis and lymphangiogenesis in SCSTs D2-40 (lymphatic marker)» Most tumors had absent or low LVD» Clinically, only 3 patients of 65 stained slides had LN metastases (recurrent disease)» 3 tumors with nodal metastasis had LVD of 38.5 vessels/hpf» Tumors without nodal metastasis had LVD of 2.7 vessels/hpf (p < 0.001)
50 Clinical relevance of angiogenesis and lymphangiogenesis in SCSTs VEGF» Present in 99% of all samples to some degree» Overexpressed in 35% of samples» Related to high MVD
51 VEGF Overexpression and Angiogenesis VEGF: Overexpression with high score of 12 VEGF: No overexpression with low overall score of 4
52 Why is VEGF important? Because we have anti-vegf Bevacizumab (Avastin) is a monoclonal antibody that targets VEGF!
53
54 But does VEGF mean that there are really more blood vessels? CD31: High MVD score, mean MVD of 48.4 CD31: Low MVD score, mean MVD of 7.4
55 What does that tell us about GCT behavior? CD31 (MVD)» High MVD in 41% of samples; associated with» Shorter DFS (16.7 vs months, p = )» Increased risk of recurrence (p < 0.04)» Shorter OS (108.6 vs m, p < 0.001)» Related to VEGF expression (p = 0.009)» Associated with distant metastasis (p < 0.001)
56 Question: If angiogenesis is important, does that translate clinically?
57 8 patients underwent treatment with Avastin for recurrent disease» 1 CR» 2 PRs» 2 stable» 3 progressed Response rate 38%, clinical benefit rate of 63% PFS 7.2 months, OS after bev of 23.6 months -Tao X, Brown J et al (2009) Gynecol Oncol 114:
58 GOG 251 A Phase II Study of Bevacizumab in the Treatment of Recurrent Sex Cord-Stromal Ovarian Tumors» Accrual complete (36 patients) as of January 31, 2011» Will have the results very shortly.» Designing next trial
59 Featured Poster Presentation Secondary cytoreductive surgery: A key tool in the management of recurrent ovarian sex cordstromal tumors D. Namaky1, P. Ramirez2, M. Munsell2, A. Nick2, D. Gershenson2, J. Brown2 Good Samaritan Hospital, Cincinnati, OH, 2University of Texas M.D. Anderson Cancer Center, Houston, TX 1 Rationale: What is the role of surgery when GCT recurs?
60 Results 105 patients Median progression-free survival (PFS) 33.1 months Median overall survival months Successful in achieving an optimal result (<1 cm left) in 75% of patients!
61 Results
62 Results 71.7% of patients (n=76) recurred more than once» 66.2% of these patients had multiple surgeries Each time, the cancer-free interval was shorter More likely to come back in a distant site at the second recurrence (24%) vs. the first recurrence (15%)» Helps with knowing where to look» Surgery may be useful over and over again!
63 Conclusions Most patients with recurrent ovarian sex cord-stromal tumors can be optimally cytoreduced Secondary cytoreductive surgery should be considered as a treatment option for selected patients with recurrent disease
64 Juvenile Granulosa Cell Tumor
65
66 Research Requires Funding! NCI» Cooperative groups GOG» SPOREs, PPG, R01, R21 Industry Foundations» Foundation for Women s Cancer» OCRF Local institutions
67 Thank you!
68 Acknowledgements David M. Gershenson, M.D. Michael T. Deavers, M.D. Anil K. Sood, M.D. Ljiljana Milojevic
69 Acknowledgements
Diagnosi, inquadramento clinico e chirurgia
Tumori germinali, stromali e forme rare : stato dell arte, novità e prospettive Caravaggio 10-12 giugno 2010 Giorgia Mangili IRCCS San Raffaele Milano Diagnosi, inquadramento clinico e chirurgia SEX-CORD
More informationNon-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
23 (Supplement 7): vii20 vii26, 2012 doi:10.1093/annonc/mds223 Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up N. Colombo 1,5, M. Peiretti 1, A.
More informationRESEARCH ARTICLE. Usanee Chatchotikawong 1, Irene Ruengkhachorn 1 *, Chairat Leelaphatanadit 1, Nisarat Phithakwatchara 2. Abstract.
RESEARCH ARTICLE 8-year Analysis of the Prevalence of Lymph Nodes Metastasis, Oncologic and Pregnancy Outcomes in Apparent Early-Stage Malignant Ovarian Germ Cell Tumors Usanee Chatchotikawong 1, Irene
More informationProspective study evaluating a strategy of surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor (KGOG 3033)
Prospective study evaluating a strategy of surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor (KGOG 3033) Investigators/Collaborators: Jeong-Yeol Park, M.D., Ph.D. Department
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationChristian Marth, MD, PhD Department of Obstetrics and Gynecology Innsbruck Medical University Innsbruck, Austria
Christian Marth, MD, PhD Department of Obstetrics and Gynecology Innsbruck Medical University Innsbruck, Austria Classification of Ovarian Neoplasms Origin Surface Epithelial Cells Germ Cells Sex Cord
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationPrimary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz
Primary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz Epithelial Subtypes Serous Endometrioid Mucinous Transitional Clear Cell Mixed Undifferentiated Squamous Ovarian Surface Epithelium Naora et al.,
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationHow to fight a silent killer: Lessons learned from Ovarian Cancer. Stephen A. Cannistra, M.D.
How to fight a silent killer: Lessons learned from Ovarian Cancer Stephen A. Cannistra, M.D. How to fight a silent killer: Lessons learned from Ovarian Cancer Ovarian cancer is not common but is highly
More informationPrognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases
J Gynecol Oncol Vol. 20, No. 3:158-163, September 2009 DOI:10.3802/jgo.2009.20.3.158 Original Article Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationPoor-prognostic advanced Germ Cell Tumors
14-10-16 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationFellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationTarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationGYNECOLOGIC MALIGNANCIES: Ovarian Cancer
GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss
More informationOvarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
More informationGynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy
Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Stephanie Yap, M.D. University Gynecologic Oncology Northside Cancer Institute Our Learning Objectives Review survival rates,
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationStudy Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationA stratified clinical approach to uterine sarcoma
A stratified clinical approach to uterine sarcoma Martee L. Hensley, MD Memorial Sloan-Kettering Cancer Center Gynecologic Medical Oncology Weill Cornell Medical College New York, NY USA Disclosure slide
More informationPrognostic factors in sex cord stromal tumors of the ovary
Research article Prognostic factors in sex cord stromal tumors of the ovary Achraf HADIJI 1, Tarak DAMAK 1, Lamia CHARFI 2, Jamel BEN HASSOUNA 1, Imen OUESLETI 1, Riadh CHARGUI 1, Khaled RAHAL 1. 1 Service
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationCancer: recent advances and implications for underwriting
Cancer: recent advances and implications for underwriting Robert Rubens Select 74 Bristol 25 February 2010 Agenda Epidemiology - changing mortality Evidence-base for underwriting breast cancer ovarian
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationGerm Cell Tumors. Karim Fizazi, MD, PhD Institut Gustave Roussy, France
Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Surveillance for stage I GCT NSGCT A 26 year-old patient had a orchiectomy revealing embryonal carcinoma (40%), seminoma (40%) and
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationTrabectedina + PLD nel trattamento del carcinoma ovarico. Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano
Trabectedina + PLD nel trattamento del carcinoma ovarico Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano The old definition of Recurrent Ovarian Cancer P R I M A R Y T H E
More informationFellow GU Lecture Series, Testicular Cancer. Asit Paul, MD, PhD 02/06/2018
Fellow GU Lecture Series, 2018 Testicular Cancer Asit Paul, MD, PhD 02/06/2018 Rare cancer worldwide, approximately 1% of all male cancers There is a large difference among ethnic/racial groups. Rates
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationTrial record 1 of 1 for:
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,
More informationGonadal non-germ Cell Tumors
TREP Meeting Trieste April 12, 2012 Gonadal non-germ Cell Tumors C. Virgone G. Cecchetto TREP project (January 2000-March 2012) Gonadal non-germ Cell Tumors Various and different histotypes including:
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationManagement of Stage Ic-IV Malignant Ovarian Germ Cell Tumours
Management of Stage Ic-IV Malignant Ovarian Germ Cell Tumours Michael J Seckl Charing Cross Hospital Campus of Imperial College NHS Healthcare Trust Imperial College London, UK 9-12th June 2010 Caravaggio
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationGranulosa Cell Tumor Monitoring and Treatment. Outline: 1. Surgery 2. Adjuvant 3. Chemo 4. Hormonal 5. Investigational. Whole Genome Sequencing
Potential Conflicts of Interest capped at a level befitting an academic role Lo B. Serving Two Masters 2010;362:669-671 Granulosa Cell Tumor Monitoring and Treatment Richard T. Penson, MD, MRCP Clinical
More informationRTWG - Carcinosarcoma. Max Parmar, Jane Bryce, Andreas Poveda, Amit Oza
RTWG - Carcinosarcoma Max Parmar, Jane Bryce, Andreas Poveda, Amit Oza Overview Background Questions urgent and timely investigations? Proposed Approach Regulatory Solutions Output Carcinosarcomas Background
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationChemotherapy in Gynecologic Malignancies
Chemotherapy in Gynecologic Malignancies Dr U.D.Bafna Professor & Head, Department of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bangalore Chemotherapy in solid tumors is mainly adjuvant
More informationSurvival impact of cytoreductive surgery ın advanced stage EOC
Survival impact of cytoreductive surgery ın advanced stage EOC Ayhan Ali, MD Baskent University School of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology 1 OVARIAN CANCER
More informationRANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED
RANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED CHEMOTHERAPY FOR HIGH- RISK STAGE I AND STAGE II-IV OVARIAN
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationAnnual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013
bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationSee the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done.
About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. What Is
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More informationOVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary)
1 OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary) Source: UpToDate 2015, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationAdvanced/Recurrent Endometrial Cancer: First-line Treatment should be Chemotherapy PRO. Gini Fleming GCIG June 1, 2017
Advanced/Recurrent Endometrial Cancer: First-line Treatment should be Chemotherapy PRO Gini Fleming GCIG June 1, 2017 EC First-Line Chemotherapy Currently carboplatin/paclitaxel Provides tumor shrinkage
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationGCIG Rare Tumor Working Group Report. David M. Gershenson Isabelle Ray-Coquard
GCIG Rare Tumor Working Group Report David M. Gershenson Isabelle Ray-Coquard Thursday 31 st May 2012 Ted Trimble IRCI - Aims To facilitate the development of international clinical trials of treatments
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationMarcello Deraco M.D. Responsible Peritoneal Malignancies
Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationCo-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG
OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationsurgical staging g in early endometrial cancer
Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationU T C H. No disclosure
D U GOG T C H Randomized phase 3 trial comparing primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer: OVHIPEC-2 Willemien van
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationRare ovarian tumours Page 1 of 6 Ovacome
Fact sheet 12 Rare ovarian tumours Ovacome is a national charity providing advice and support to women with ovarian cancer. We give information about symptoms, diagnosis, treatment, research and screening.
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bevacizumab (Avastin) for Cervical Cancer March 23, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bevacizumab (Avastin) for Cervical Cancer March 23, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationInvasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous
Note: If available, clinical trials should be considered as preferred treatment options for eligible patients (www.mdanderson.org/gynonctrials). Other co-morbidities are taken into consideration prior
More informationRecurrent ovarian steroid cell tumor, not otherwise specified managed with debulking surgery, radiofrequency ablation, and adjuvant chemotherapy
Case Report Obstet Gynecol Sci 2014;57(6):534-538 http://dx.doi.org/10.5468/ogs.2014.57.6.534 pissn 2287-8572 eissn 2287-8580 Recurrent ovarian steroid cell tumor, not otherwise specified managed with
More informationPresentation of two patients with malignant granulosa cell tumors, with a review of the literature
Tamura et al. World Journal of Surgical Oncology 2012, 10:185 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Presentation of two patients with malignant granulosa cell tumors, with a review of the literature
More informationAnshuma Bansal 1 Bhavana Rai
DOI 10.1007/s13224-016-0926-7 ORIGINAL ARTICLE Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationALIENOR GINECO-OV222/ENGOT-OV7
GCIG RARE TUMOUR COMMITTEE Closed Trial status update ISABELLE RAY-COQUARD ALIENOR GINECO-OV222/ENGOT-OV7 Trial setting: Sex chord-stromal ovarian tumors Study Design: Randomized, open label, phase II
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationALTHOUGH RELATIVELY uncommon, dysgerminoma
Outcome and Reproductive Function After Chemotherapy for Ovarian Dysgerminoma By Molly Brewer, David M. Gershenson, Cynthia E. Herzog, Michele Follen Mitchell, Elvio G. Silva, and J. Taylor Wharton Purpose:
More information